Human Aurora2 was originally identi®ed by its close homology to yeast IPL1 and¯y aurora, which are key regulators of chromosome segregation and a family of serine/threonine kinases. Here we demonstrate that the Aurora2 protein is degraded rapidly after G2/M phase release in mammalian cells. Aurora2 protein has a rapid turnover rate with a half-life of approximately 2 h. In eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for the targeted degradation of unstable proteins. The treatment of mammalian cells with proteasome inhibitors blocks Aurora2 degradation. Furthermore, Aurora2 is polyubiquitinated in vivo and in vitro using anaphase-promoting complex (APC). These results demonstrate that Aurora2 protein is turned over through the APC-ubiquitin-proteasome pathway.
Introduction
The yeast IPL1 and Drosophila aurora are required for chromosome segregation and centrosome maturation and constitute a family of serine/threonine kinases (Francisco et al., 1994; Glover et al., 1995) . The IPL1 gene was identi®ed originally in a screen for yeast mutants that increase in ploidy (Francisco et al., 1994) . The yeast IPL1 may regulate kinetochore function via phosphorylation of Ndc10p (Biggins et al., 1999) . Embryos derived from aurora mutant mothers display closely paired centrosomes and monopolar spindles (Glover et al., 1995) . Recently, mammalian homologs have been identi®ed. All of these homologs associate with mitotic structures such as the spindle and the centrosome, and both the message and protein levels are cell-cycle regulated. Among the Aurora/IPL1 kinase family, human AIK/STK15/BTAK/ARK1/AuroraII (Bischo et al., 1998; Kimura et al., 1997; Shindo et al., 1998; Zhou et al., 1998) and mouse IAK1/AYK1 (Gopalan et al., 1997; Yanai et al., 1997) appear to constitute a subfamily, because these protein kinases have closely related N-terminal as well as C-terminal kinase domains. Here we refer to these proteins as Aurora2 according to a recent review (Bischo and Plowman, 1999) . Human Aurora2 is ampli®ed in cancer cells and overexpression of Aurora2 can transform cells (Bischo et al., 1998; Zhou et al., 1998) . These ®ndings suggest that Aurora2 protein is important for maintaining cell cycle progression and genomic stability in mammalian cells.
The ubiquitin-proteasome pathway is the major system in the eukaryotic cell for the selective degradation of short-lived regulatory proteins (Ciechanover, 1998) . A common feature of proteasomemediated protein degradation is the covalent attachment of ubiquitin, a 76-amino acid protein, to e-amino lysyl groups of proteins targeted for degradation followed by the formation of polyubiquitin chains attached covalently to the targeted protein. The formation of ubiquitin-protein conjugates requires three components: a ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2), and a multimeric ubiquitin ligase (E3). Two E3 complexes were discovered through studies of cell cycle regulation: the cyclosome/APC and the SCF complex. Ubiquitinated proteins are typically degraded by a large protease complex called the 26S proteasome in an ATPdependent manner. The ubiquitin-proteasome pathway plays an important role in various cellular processes such as cell-cycle regulation, signal transduction, dierentiation, antigen processing, and degradation of tumor suppressors (Ciechanover, 1998; Varshavsky, 1997) .
The events of late mitosis, from sister chromosome separation to exit from mitosis, are governed by ubiquitin-dependent proteolysis of key regulatory proteins. A major step in this destruction is catalyzed by the APC. An important degradation signal, the socalled destruction box or D-box, was de®ned by analysis of the N-terminal region in cyclin B (Glotzer et al., 1991) . The destruction box sequences appear to be quite variable except for the minimal RXXL. Mutations in the destruction box stabilize cyclins and severely reduce or abolish their ubiquitination (Amon et al., 1994; Glotzer et al., 1991; Stewart et al., 1994) . The mechanistic role of the destruction box is still unknown. It does not serve as a phosphorylation or ubiquitination site (Ciechanover, 1998) . On the other hand, essential mitotic regulators, such as the polo-like kinase Plk1, lacking the destruction box are speci®c substrates of APC (Fang et al., 1998) .
It has been shown that important cell cycle regulators including the cyclins, Cdk inhibitors, p53 and myc, are all degraded by the ubiquitin-proteasome pathway (Maki et al., 1996; Murray et al., 1989; Pagano et al., 1995; Salghetti et al., 1999) . It is thought that periodic degradation of these proteins is essential for cell cycle progression. Our results indicate that the APC-ubiquitin-proteasome pathway mediates the rapid turnover of Aurora2.
Results

Characterization of the monoclonal antibody M11-17 for Aurora2
Recombinant GST-tagged full-length human Aurora2 was used to make monoclonal antibodies against the Aurora2. The speci®city of the M11-17 antibody was tested with immunoblots of transfected COS cells. This antibody recognized a single protein of the expected molecular weight in whole cell lysates from COS cells transfected with glu-tagged Aurora2 (Figure 1a) . Importantly, the M11-17 antibody could not recognize either Aurora1 or Aurora2(DN) protein ( Figure 1a ). Aurora2 had previously been shown to be cell cycle regulated (Bischo et al., 1998; Gopalan et al., 1997; Kimura et al., 1997; Shindo et al., 1998) . HeLa cells were synchronized by a double thymidine block, released from their G1/S arrest, and sampled for 24 h, during which time they completed S phase, G2, mitosis, and G1. Aurora2 was immunoblotted using the lysates of HeLa cells. Consistent with the earlier ®ndings, Aurora2 protein was absent through G1 phase, began to accumulate in S phase, and peaked late in mitosis ( Figure 1b) . As a control, the MAPK protein level did not change signi®cantly during the cell cycle progression. On indirect immuno¯uorescence microscopy of exponentially growing HeLa cells, this antibody only stained the centrosome and spindle pole region in mitotic cells and not any recognizable structures or compartments in interphase cells ( Figure  1c ). The faint cytoplasmic staining was a background, because the second antibody alone stained the cytoplasmic region at the same level (data not shown). The Aurora2 immunostaining is consistent with that reported elsewhere using polyclonal antibody (Bischo et al., 1998; Gopalan et al., 1997; Kimura et al., 1997; Shindo et al., 1998) . Therefore, the M11-17 antibody is the ®rst monoclonal antibody against Aurora2 protein and speci®c for the N-terminus of the protein.
Aurora2 is unstable
Aurora2 protein levels decreased rapidly after G2/M phase release in HeLa cell lysates (Figure 2a ), while the MAPK protein level did not change signi®cantly. Next, we investigated the turnover rate of Aurora2 using pulse-chase experiments. The experiments were performed with either HeLa cells or transfected COS cells transiently expressing glu-tagged Aurora2. Exponentially growing cells were labeled for 1 h with 35 Smethionine/cysteine and then chased for various periods of time. The Aurora2 proteins were subsequently immunoprecipitated with the M11-17 antibody or anti-glu monoclonal antibody, and separated by SDS ± PAGE (Figure 2b) . Following SDS ± PAGE and autoradiography, the radioactivity of the bands was quanti®ed to determine the half-life (t 1/2 ) of the proteins. As is evident from Figure 2b , endogenous Aurora2 in HeLa cells has a rapid turnover rate with a half-life of approximately 2 h (Figure 2c ). In addition, the turnover rate of glu-Aurora2 expressed in COS cells was very similar to that in HeLa cells. Thus by both methods, Aurora2 was found to be rapidly degraded.
Inhibition of endogenous and transiently expressed Aurora2 degradation by proteasome inhibitors
It is well established that clasto-lactacystin b-lactone (cLL), N-acetyl-Leu-Leu-norleucinal (LLnL) and MG132 inhibit proteaseome-mediated proteolysis, and that they lead to an accumulation of proteins that are usually metabolized by this pathway. cLL is a very speci®c inhibitor of the proteasome with trypsin-like and chymotrypsin-like inhibitory activities, as well as weak peptidylglutamyl peptidase inhibitory activities (Fenteany and Schreiber, 1998) . The peptide aldehyde Figure 3a , Aurora2 degradation after G2/M phase release was completely inhibited by proteasome inhibitors. LLnL also exhibits signi®cant inhibitory activity for the cysteine protease calpain (Rock et al., 1994) . However, it is unlikely that calpain played a signi®cant role, because Aurora2 degradation was not prevented by the calpain inhibitor, N-acetyl-Leu-Leumethional (ALLM) (Figure 3a , lower panel). Second, treatment of HeLa cells with proteasome inhibitors for 12 h resulted in a marked increase of endogenous Aurora2 protein levels to various extents in vivo (whereas the MAPK protein level remained unaected) ( Figure 3b ). Together these results indicate that the proteasome plays a major role in the regulation of Aurora2 stability.
To examine whether transiently expressed Aurora2 follows the same mode of regulation as the endogenous protein, COS cells were transiently transfected with a glu epitope-tagged Aurora2 expression vector and, 24 h after transfection, the cells were exposed to proteasome inhibitors. These conditions were identical to those used above when studying endogenous Aurora2 protein levels. After induction for 12 h, the cells were harvested and analysed by immunoblotting for the presence of the transfected protein. As seen in Figure  3c , in analogy to the endogenous Aurora2, exposure of the transfected cells to proteasome inhibitors markedly increased the levels of epitope-tagged Aurora2, indicating that the transiently expressed protein is also rapidly degraded via the proteasome.
Ubiquitination of Aurora2 in vivo
The results presented so far strongly suggested that Aurora2 was subjected to the ubiquitin-proteasome pathway. To more directly assess whether Aurora2 can form ubiquitin conjugates, a recently developed assay for the detection of ubiquitinated proteins was employed (Treier et al., 1994) . COS cells were COS cells transiently transfected with glu-Aurora2/pMT3 were treated with either 25 mM LLnL, 25 mM MG132, or vehicle only (7) for 12 h before preparation of whole cell extracts. Twenty-mg aliquots of the extracts were analysed by immunoblotting with anti-glu (upper panel) or with anti-MAPK antibodies (lower panel). Samples were run in duplicate transfected with a glu-Aurora2 expression vector, along with either histidine-epitope-tagged ubiquitin (His-Ub), or the corresponding control vector. Cell extracts were prepared under denaturing conditions and puri®ed on nickel-NTA beads (Campanero and Flemington, 1997) . Denaturing conditions were used to prevent copuri®ca-tion of noncovalently associated proteins and to prevent degradation or de-ubiquitination of proteinubiquitin conjugates. Immunoblot analysis of column elutes with an anti-glu antibody revealed a ladder of Aurora2-immunoreactive proteins in the His-Ub elute, but not in control elutes (Figure 4a ). In addition, Aurora2 reactivity was not detected in elutes from cells transfected with the His-Ub vector alone, although these extracts contained fair amounts of ubiquitinated proteins (data not shown).
In vitro ubiquitination of Aurora2
Aurora2 protein began to accumulate in G2, was stable throughout mitosis and rapidly disappeared in early G1 (Figure 1b) . The cell-cycle regulated proteolysis of Aurora2 suggested that it is a target of APC. To determine whether polyubiquitination of Aurora2 was dependent upon the presence of APC, in vitro ubiquitination was carried out in the presence of a mouse E1, human E2-C as E2, and human puri®ed APC. Human APC was prepared by immunoprecipitation with anti-hCdc27 antibody from HeLa cell lysate prepared 1 h after the release from a thymidine/ nocodazole block. An anti-Ras antibody was used in the immunoprecipitations as a negative control. When human APC was added to the reaction mixture instead of control beads, a ladder of higher molecular mass appeared (Figure 4b,c) . Thus, Aurora2 was polyubiquitinated in vitro and a substrate of APC.
Aurora2 does not have a functional destruction box
The destruction of many APC targets requires the presence of the destruction box. The N-terminus of human Aurora2 contains one stretch ( To determine whether polyubiquitination of Aurora2 was dependent upon the presence of destruction box sequences, these mutants were subjected to an in vivo ubiquitination assay. The ubiquitination level of Aurora2(D2m) was signi®cantly lower than those of wild type (wt) Aurora2 and other mutants (Figure 5a ), whereas expression levels of transiently expressed wild type and mutants of Aurora2 were equal. This result indicates that the second stretch ( 205 RVYLILEYA) of human Aurora2 might serve as a signal for polyubiquitination. To examine the stability of the mutant Figure 4 Aurora2 is polyubiquitinated in vivo and in vitro. (a) COS-7 cells were transiently transfected with an expression construct encoding glu epitope-tagged Aurora2 either in the presence or absence of an expression construct encoding histidine-tagged Ub (His-Ub). Following transfection, histidine-tagged (ubiquitinated) proteins were puri®ed using nickel-NTA beads and resolved by SDS ± PAGE, and glu-tagged proteins detected by immunoblotting. The ubiquitinated Aurora2 appears as multiple forms. The arrow indicates the position of free Aurora2. (b) The in vitro ubiquitination reaction was applied to glu-Aurora2 immunoprecipitated from transfected COS cells. Glu-Aurora2 bound to beads was incubated with ATP and ubiquitin together with either mouse E1 and human E2-C as E2 or control buer, along with human puri®ed APC or control beads. Human APC was immunoprecipitated with anti-Cdc27 antibody from HeLa cell lysate prepared 1 h after the release from a thymidine/nocodazole block. An anti-Ras antibody was used in the immunoprecipitations as a negative control. Glu-tagged proteins were detected by immunoblotting using the anti-glu antibody. A ladder of higher molecular mass appeared when human APC was added to the reaction mixture with mouse E1 and human E2-C as E2. Aurora2 was polyubiquitinated in vitro and a substrate of APC. (c) In vitro ubiquitination assay with GST-ubiquitin instead of ubiquitin. The resulting immunoprecipitate was analysed by immunoblotting with anti-GST monoclonal antibody Oncogene Degradation of Aurora2 K Honda et al Aurora2 protein, pulse-chase experiments were then conducted ( Figure 5b ). The turnover rate of Aurora-2(D2m) in COS cells was very similar to that of wild type Aurora2. The single alanine mutant of the arginine residue would not be sucient. We next made Aurora2(D2mS), which is the alanine mutant of Aurora2(D2m) at the leucine residue conserved in all the destruction boxes. The ubiquitination level of Aurora2(D2mS) was the same as that of Aurora-2(D2m), and lower than that of wild type Aurora2 (Figure 5c ). The turnover rate of Aurora2(D2mS) in COS cells was the same as that of wild type Aurora2 (Figure 5d) . Thus, the second stretch ( 205 RVYLILEYA) of human Aurora2 might serve as a signal for polyubiquitination, but the stretch alone was not sucient for the degradation signal. Aurora2 protein did not contain a functional destruction box.
Discussion
Our interest in the role of Aurora2 in the cell cycle and signal transduction inspired the analysis on the regulation of Aurora2 stability presented here. Previous works and this study have established that the protein level of Aurora2 is tightly cell-cycle regulated (Bischo et al., 1998; Gopalan et al., 1997; Kimura et al., 1997; Shindo et al., 1998) . The expression pattern and short half-life of Aurora2 protein suggests that it is a substrate of APC. The degradation of Aurora2 by the APC-ubiquitin-proteasome pathway reported here could, therefore, represent a mechanism to regulate the turnover of Aurora2.
For the detection of endogenous Aurora2, we made a monoclonal anti-Aurora2 antibody, M11-17, because of the speci®city. The monoclonal antibody recognizes mono-speci®c Aurora2 as con®rmed by immunoblotting of total cell extract and immuno¯uorescence analysis of cultured cells. An epitope of M11-17 was found to lie in the N-terminal domain of Aurora2. In this study, we used two independent experimental systems to analyse the regulation of the Aurora2 degradation; one was endogenous Aurora2 in HeLa cells and the other was exogenous Aurora2 overexpressed in COS cells. The turnover of exogenous and endogenous Aurora2 has the same kinetics. And the two independent systems indicated that it is well regulated by the ubiquitin-proteasome pathway.
Mammalian cells contain two distinct major proteolytic pathways. One important piece of non-lysosomal machinery for the degradation of intracellular proteins is the ubiquitin-proteasome pathway (Ciechanover, 1994) . It has been shown that important cell cycle regulators including the cyclins, Cdk inhibitors, p53 and myc, are all degraded by the ubiquitin-proteasome pathway (Maki et al., 1996; Murray et al., 1989; Pagano et al., 1995; Salghetti et al., 1999) . It is thought that periodic degradation of these proteins is essential for cell cycle progression. In an eort to characterize the mechanisms of Aurora2 degradation, we investigated the eect of inhibitors of the 26 S proteasome on Aurora2 protein levels. Both a highly speci®c lactacystin metabolite cLL and less-speci®c inhibitors (LLnL and MG132) produced a marked accumulation of Aurora2 (Figure 3b,c) . And Aurora2 degradation after the G2/M phase was completely prevented by proteasome inhibitors, but not by the calpain inhibitor, ALLM (Figure 3a, lower panel) . To address the possible involvement of polyubiquitination in the targeting of Aurora2 for destruction, we used an in vivo ubiquitination assay where, upon transient expression of anity-tagged ubiquitin, target proteins can be isolated using an anity resin (Treier et al., 1994) . This assay was employed in the presence of a proteasome inhibitor to prevent rapid destruction of the conjugated complexes. Without a proteasome inhibitor, it was dicult to detect the conjugated complexes (data not shown). Aurora2 was eectively copuri®ed in the presence of histidine-tagged ubiquitin (Figure 4a ). This eect was selective for Aurora2 because no immunoreactivity was detected in the absence of histidine-tagged ubiquitin. Taken together, these results indicate that the ubiquitin-proteasome pathway mediates the rapid turnover of Aurora2.
As ubiquitin ligase, two E3 complexes were discovered through studies of cell cycle regulation: the cyclosome/APC and the SCF complex. APC was activated during mitosis and the G1 phase (Fang et al., 1998) . The expression pattern and rapid proteolysis of the Aurora2 protein suggests that it is a substrate of APC. E2-C and the E3 ubiquitin ligase activity were associated with APC (Townsley et al., 1997) . To assess this issue, in vitro reconstituted ubiquitination assay was performed with human recombinant E2-C as E2 and puri®ed human APC. As expected, Aurora2 was polyubiquitinated using human E2-C ubiquitin-conjugating enzyme and puri®ed human APC ( Figure  4b,c) . APC ubiquitinates proteins such as Cut2/Pds1 and Cyclin B whose subsequent degradation by the 26S proteasome is essential for the initiation of sister chromatid separation at the metaphase-anaphase transition and exit from mitosis, respectively (Fang et al., 1998) . And the APC regulators, Cdc20/p55Cdc and Cdc5/Plk-1, are also polyubiquitinated by APC itself (Koepp et al., 1999) . Similarly, many key regulators of the cell cycle are ubiquitinated by APC. Therefore, Aurora2 might be a cell cycle regulator. The identi®ca-tion of substrate(s) phosphorylated by Aurora2 is of obvious interest.
The destruction of many APC targets requires the 9-residue conserved motif known as the destruction box (Ciechanover, 1998) . The destruction box is usually located *40 ± 50 amino acid residues from the Nterminus. The N-terminus of human Aurora2 contains one stretch ( 56 RVPLQAQKL) similar to the destruction box. But the point-mutated Aurora2(D1m) was also polyubiquitinated in an in vivo assay system. The second stretch ( 205 RVYLILEYA) in the kinase domain might serve as a signal for polyubiquitination, but the stretch was not the signal for proteolysis. On the other hand, essential mitotic regulators such as the polo-like kinase Plk1, lacking the destruction box, are speci®c substrates of APC (Fang et al., 1998) . Aurora2 and Plk1 presumably contain other structural features for the degradation signal. The recognition machinery for proteolysis remains to be explored.
Materials and methods
Materials
All proteasome inhibitors were maintained in dimethyl sulfoxide (DMSO) and were diluted in media before being applied to cell cultures. N-acetyl-Leu-Leu-norleucinal (LLnL; 5 mM stock) and N-acetyl-Leu-Leu-methional (ALLM) were purchased from Sigma and used at a ®nal concentration of 25 mM; clasto-lactacystin b-lactone (cLL) and MG132 (5 mM stocks) were purchased from Calbiochem and used at a ®nal concentration of 25 mM. Polyclonal antibody to MAPK was obtained from New England Biolabs. Anti-glu monoclonal antibody and anti-Ras polyclonal antibody were generous gifts from Dr Larry A Feig (Tufts University, Boston, MA, USA).
Plasmid constructs
Human Aurora1 and Aurora2 (Shindo et al., 1998) cDNAs were obtained by reverse transcription-polymerase chain reaction using total RNA from DLD-1 colon cancer cells. Aurora2(DN) is an N-terminal deletion mutant (amino acids 1 ± 61) of Aurora2. To create a mammalian expression vector, cDNA was inserted into an altered version of pMT3 that contained a modi®ed glu (MEFMPME) 5' to the cloning site (Urano et al., 1996) . For recombinant Aurora2, the fulllength coding sequence of Aurora2 was subcloned into pGEX4T-2 (Amersham-Pharmacia). Expression plasmid encoding histidine-tagged ubiquitin (Treier et al., 1994) was a generous gift from Dr Dirk Bohmann (EMBL, Heidelberg, Germany).
Monoclonal antibody generation
Recombinant GST-tagged Aurora2 was used to immunize mice, and serum titers were monitored by immunoblot using the lysate of COS cells transfected with glu-Aurora2/pMT3. After multiple injections, spleens were harvested, and splenic lymphocytes were isolated and fused to myeloma cell line NS-1. Clonal populations of fusion cells were screened for antibody production by enzyme-linked immunosorbent assay, and productive cell wells were cloned to monoclonal lines by serial dilutional screening (Urano et al., 1993) . Five monoclonal antibodies were prepared that also detected protein in immunoblots. The M11-17 monoclonal antibody was used for the present studies. Highly concentrated antibody was obtained from murine ascites after the intraperitoneal injection of hybridoma cells.
Cell cycle synchronization
HeLa cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS; Sigma). Ten cm tissue culture dishes were seeded at a density of 3610 6 with exponentially growing HeLa cells. For S phase synchronization, HeLa cells were synchronized by double thymidine treatment (Kimura et al., 1997) . The following day, thymidine (Sigma) was added to the media to a ®nal concentration of 2.5 mM and the plates were incubated for 16 h at 378C. The plates were then washed three times with phosphate-buered saline (PBS) and normal growth medium was added. Following 8 h at 378C, cells were treated with the drug for an additional 16 h. For M phase synchronization, cells were ®rst treated with 2.5 mM thymidine, released into fresh medium for 3 h, and then blocked with medium containing 400 ng/ml nocodazole for 8 h. To release them from the drug treatment, cells were washed with PBS three times and normal growth medium was added.
Indirect immunofluorescence microscopy
HeLa cells were plated on poly (L-lysine)-coated coverslips at *25% con¯uency. The following day the cells were washed once with ice-cold PBS and ®xed with methanol at 7208C for 10 s. The cells were washed three times with ice-cold PBS and incubated for 5 min at room temperature in PBS containing 0.05% Triton X-100. The permeabilized cells were washed three times with ice-cold PBS and then covered with a solution of 10% bovine serum albumin in PBS and incubated for 30 min at room temperature. The M11-17 antibody was diluted, placed as a drop on the coverslips, and incubated for 45 min at 378C in a humidi®ed chamber. The coverslips were then washed six times with PBS and covered with a solution containing goat anti-mouse-FITC (Sigma) for 30 min in the dark at 378C in a humidi®ed chamber. The coverslips were next washed six times with PBS and attached to slides with clear nail polish.
Transient transfections
COS-7 cells were maintained in DMEM supplemented with 10% FCS. COS-7 cells (3610 5 cells in a 60 mm culture dish) were transfected with glu-Aurora2/pMT3 by the DEAEDextran method (Urano et al., 1996) .
Pulse-chase analysis
To perform the pulse-chase, cells were washed twice with warm PBS, and starved of methionine and cysteine by incubation for 30 min at 378C in 1.5 ml of methionine/ cysteine-free DMEM (Gibco ± BRL), supplemented with 10% dialyzed FCS. Following amino acid starvation, cellular proteins were pulse-labeled by incubating each plate of cells with 150 mCi of 35 S-methionine/cysteine (Tran 35 S-label; ICN) for 1 h at 378C. The radioactive medium was then removed, and the cells were washed twice in warm PBS, re-fed with DMEM supplemented with 2 mM methionine and 2 mM cysteine, and incubated for appropriate periods. Labeled proteins were recovered by immunoprecipitation. Immune complexes were detected by SDS ± PAGE and autoradiography. The radioactivity was determined with a Bioimaging analyzer MacBAS 1500 (Fuji photo ®lm).
Immunoprecipitation
HeLa cells or transfected COS cells in 60 mm dishes were lysed in 500 ml of lysis buer L (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM MgCl 2 , 1% Triton X-100, 1% NP-40, 1 mM phenylmethylsulfonyl¯uoride and 10 mg/ml aprotinin) with rocking for 15 min at 48C. The lysates were cleared by centrifugation at 12 000 r.p.m. for 5 min. The lysates were immunoprecipitated with the primary monoclonal antibody bound to protein A-Sepharose (Amersham-Pharmacia) with rocking at 48C for 75 min. The beads were washed ®ve times with 1 ml of washing buer A (50 mM Tris-HCl (pH 7.5), 25 mM NaCl, 10 mM MgCl 2 , 0.5% NP-40) and ®nally resuspended in 15 ml of 26SDS ± PAGE sample buer. The immunoprecipitated proteins were separated by SDS ± PAGE.
In vivo ubiquitination assay
Thirty-six hours after transfection, cells were treated with 25 mM LLnL for 12 h and lysed in 1 ml of buer G (6 M guanidinium-HCl/0.1 M Na 2 HPO 4 /NaH 2 PO 4 pH 8.0/10 mM imidazole) per 60 mm dish. The lysate was passed through a 26-gauge needle to reduce viscosity and then mixed on a rotator with 15 ml (settled volume) of nickel-NTA-agarose (Qiagen) for 75 min at room temperature. The beads were washed three times with 1 ml of buer G, twice with 1 ml of buer G diluted in 25 mM with Tris-HCl (pH 6.8)/20 mM imidazole 1 : 4, and twice with 1 ml of 25 mM Tris-HCl (pH 6.8)/20 mM imidazole. Puri®ed proteins were eluted by boiling the beads in 26SDS sample buer supplemented with 100 mM EDTA and analysed by immunoblotting.
Cell-cycle analysis
To monitor the cell-cycle distribution, cellular DNA content was assayed by standard techniques using propidium iodide staining. Brie¯y, 1610
6 HeLa cells were ®xed with cold 70% ethanol for 30 min at 48C. Cells were washed once with phosphate-buered saline (PBS), treated with RNase (1 mg/ ml) for 40 min at 378C and resuspended in propidium iodiode (50 mg/ml) at room temperature for 20 min to stain cellular DNA. Events were collected and analysed on a FACScan (Becton Dickinson).
In vitro ubiquitination assay
In vitro ubiquitination assay was performed by the modi®ed method of Honda and Yasuda (1999) . The immunoprecipitate of the COS cell extract expressing glu-Aurora2 with antiglu antibody was mixed with 30 ml of 50 mM Tris (pH 7.4), 5 mM MgCl 2 , 2 mM ATP, bovine ubiquitin (Sigma, 15 mg), mouse recombinant E1 (300 ng), human recombinant E2-C (300 ng) and human puri®ed APC. Human APC was immunoprecipitated with anti-Cdc27 antibody from HeLa cell lysate prepared 1 h after the release from a thymidine/ nocodazole block. An anti-Ras antibody was used in the immunoprecipitations as a negative control. After the reactions had been carried out at 258C for 30 min, Protein A beads conjugated to glu-Aurora2 were pulled down by centrifuge. Each reaction mixture was subjected to SDS ± PAGE on a 10% gel, followed by immunoblotting analysis with the anti-glu antibody. In order to con®rm that Aurora2 had been ubiquitinated, identical reaction mixtures to those described above were subjected to in vitro ubiquitination in the presence of GST-ubiquitin (Aniti Research Products) instead of ubiquitin. The resulting immunoprecipitate was analysed by immunoblotting with anti-GST monoclonal antibody (Amersham-Pharmacia).
